– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Change from subcutaneous to intravenous abatacept seen as safe, effective in low disease activity RA
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis in low disease activity or remission can safely and effectively be switched ...
hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
March 6, 2006 (Miami Beach) — A subcutaneous formulation of immunoglobulin replacement therapy ( Vivaglobin) produces results in primary immune deficiency diseases (PIDD) that are similar to those for ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said a subcutaneous (under the skin) formulation of Tecentriq showed to be as good as an intravenous (IV) infusion of the drug in a study consisting of ...
Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and ...
When deciding whether to use subcutaneous (SubQ) or intravenous (IV) therapies, clinicians must weigh several clinical and practical factors. One of the first considerations is the type of cancer ...
The CheckMate 67T trials revealed that subcutaneous nivolumab was noninferior to intravenous nivolumab for the treatment of advanced or metastatic clear cell renal cell carcinoma. Subcutaneous ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results